Eisai Seeks Lunesta Approval In Japan After Phase III Data, But Disease Awareness Is A Challenge
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Eisai announced Sept. 15 positive results from a Japanese Phase II/III efficacy study and a Phase III safety study for Lunesta (eszopiclone), giving the company adequate data to seek approval for the drug from Japan's Ministry of Health, Labor and Welfare in fiscal year 2010
You may also be interested in...
Lorqess' Slight Efficacy, Potential Safety Issues Leave Arena On The Hot Seat At Advisory Panel
FDA seeks input on the "slim margin" of efficacy and the adequacy of safety data for Arena's obesity drug.
Eisai's Newly Acquired Lorcaserin Faced With Regulatory Hurdle After Qnexa Advisory Committee Vote
TOKYO - Weeks after securing U.S. rights for the first of three much-touted obesity drugs, Eisai and partner Arena now face an unsure future for lorcaserin after a U.S. FDA advisory committee voted against recommending approval for Vivus' Qnexa based on safety concerns
Sepracor Signs Agreement With Eisai To Market Lunesta In Japan
Eisai will develop and market Sepracor's insomnia treatment Lunesta (eszopiclone) in Japan under an in-licensing agreement announced by the companies July 26